Wainwright reiterates Buy on Vanda stock after sleep disorder trial
H.C. Wainwright reiterated a Buy rating and $20 price target for Vanda Pharmaceuticals (VNDA) after positive Phase 3 trial results for its sleep disorder treatment. The stock is down over 10% in the past week, trading at $4.63. The study met its primary endpoint, with HETLIOZ shifting sleep onset 42.5 minutes earlier vs. placebo. Vanda reported a disappointing Q2 2026, missing earnings and revenue estimates, with an adjusted loss of $1.04 per share and revenue of $50.5 million.
How this was made
The 30-second read
Why it matters
The trial data provides a clear catalyst for valuation re‑rating, but recent earnings weakness adds risk.
Market read
Primary biotech news with direct impact on VNDA; limited spillover to broader market.
What to watch
Recent Q2 loss and revenue miss may temper enthusiasm despite trial success.
Background
Vanda Pharmaceuticals (NASDAQ:VNDA) focuses on specialty drugs; HETLIOZ targets delayed sleep‑wake phase disorder, a niche indication.
Ticker impact
H.C. Wainwright reiterated a Buy rating and raised price target after Vanda's positive Phase 3 trial results for HETLIOZ.
upward pressure as the market prices in the trial success and potential approval.
Trial met primary endpoint with a 42.5‑minute sleep onset shift; analysts already raised targets, indicating strong upside potential.
Market effects
Positive data may lift other sleep‑disorder and specialty pharma stocks.
U.S. biotech sector could see modest gains.
Limited to biotech investors; no broad market effect.
Counterpoint
If FDA approval stalls or post‑approval data disappoint, the stock could face sharp downside.
Key entities
- analystH.C. Wainwright
Equity research firm that reiterated a Buy rating on VNDA.
- analystOppenheimer
Initiated coverage with an Outperform rating.
